Currently, the combination of 5 years of tamoxifen plus 2 years of ovarian ablation with an LH-RH agonist is frequently used as a postoperative adjuvant therapy for premenopausal women with early breast cancer in many countries. The gene discussed is GNRH1; the disease is breast carcinoma.